Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
BörsenkürzelBMRA
Name des UnternehmensBiomerica Inc
IPO-datumMar 17, 1980
CEOMr. Zackary S. Irani
Anzahl der mitarbeiter63
WertpapierartOrdinary Share
GeschäftsjahresendeMar 17
Addresse17571 Von Karman Avenue
StadtIRVINE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92614
Telefon19493792875
Websitehttps://biomerica.com/
BörsenkürzelBMRA
IPO-datumMar 17, 1980
CEOMr. Zackary S. Irani
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten